Kiromic BioPharma (KRBP) 10-Q8 Nov 242024 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2024	Nov. 06, 2024
Document Information [Line Items]
Entity Central Index Key	0001792581
Entity Registrant Name	Kiromic Biopharma, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-39619
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4762913
Entity Address, Address Line One	7707 Fannin Street, Suite 200
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77054
City Area Code	832
Local Phone Number	968-4888
Title of 12(b) Security	Common Shares, par value $0.001 per share
Trading Symbol	KRBP
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,545,920

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets:
Cash and cash equivalents	$ 2,924	$ 3,204
Restricted cash	132	0
Prepaid expenses and other current assets	1,247	1,226
Total current assets	4,303	4,430
Property and equipment, net	4,847	6,175
Operating lease right-of-use asset, net	1,074	1,543
Other assets	21	21
Total Assets	10,245	12,169
Senior secured convertible promissory notes	13,640	14,000
Accounts payable	1,693	2,136
Accrued expenses and other current liabilities	1,666	1,673
Interest payable	1,460	1,938
Operating lease liability - short term	670	631
Total current liabilities	19,129	20,378
Operating lease liability - long term	404	912
Total Liabilities	19,533	21,290
Commitments and contingencies (Note 8)
Stockholders’ Deficit:
Preferred Stock, $0.0001 par value: 60,000,000 shares authorized, 33,835 and 14,000 issued and outstanding, with a liquidation preference of $40,312 and $16,205, as of September 30, 2024 and December 31, 2023, respectively	0	0
Common stock, $0.001 par value: 300,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 1,545,920 and 1,258,460 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	1	1
Additional paid-in capital	134,015	113,775
Accumulated deficit	(143,304)	(122,897)
Total Stockholders’ Deficit	(9,288)	(9,121)
Total Liabilities and Stockholders’ Deficit	$ 10,245	$ 12,169

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	60,000,000	60,000,000
Preferred stock, issued (in shares)	33,835	14,000
Preferred stock, outstanding (in shares)	33,835	14,000
Preferred stock, liquidation value	$ 40,312	$ 16,205
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	300,000,000	300,000,000
Common stock, issued (in shares)	1,545,920	1,258,460
Common stock, outstanding (in shares)	1,545,920	1,258,460

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 4,228	$ 2,677	$ 11,385	$ 6,719
General and administrative	2,375	2,875	6,684	7,903
Total operating expenses	6,603	5,552	18,069	14,622
Loss from operations	(6,603)	(5,552)	(18,069)	(14,622)
Other expense:
Interest expense	(935)	(440)	(2,957)	(1,219)
Litigation settlement	0	40	0	(1,730)
Other income	103	1,758	619	1,313
Total other expense	(832)	1,358	(2,338)	(1,636)
Net loss	(7,435)	(4,194)	$ (20,407)	$ (16,258)
Preferred Stock [Member]
Other expense:
Net loss	$ 0	$ 0
Net loss per share, basic and diluted (in dollars per share)	$ (272.82)	$ (254.26)	$ (963.64)	$ (1,294.31)
Weighted average shares outstanding, basic and diluted (in shares)	30,968	12,891	22,793	7,011
Common Stock [Member]
Other expense:
Net loss	$ 0	$ 0
Net loss per share, basic and diluted (in dollars per share)	$ (0.65)	$ (1.52)	$ (2.06)	$ (8.43)
Weighted average shares outstanding, basic and diluted (in shares)	1,545,920	1,189,989	1,432,787	1,040,190

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Series D Convertible Voting Preferred Stock [Member] Preferred Stock [Member]	Series D Convertible Voting Preferred Stock [Member] Common Stock [Member]	Series D Convertible Voting Preferred Stock [Member] Additional Paid-in Capital [Member]	Series D Convertible Voting Preferred Stock [Member] Retained Earnings [Member]	Series D Convertible Voting Preferred Stock [Member]	Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member] Preferred Stock [Member]	Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member] Common Stock [Member]	Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member] Additional Paid-in Capital [Member]	Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member] Retained Earnings [Member]	Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022											0	648,384
Balance at Dec. 31, 2022											$ 0	$ 1	$ 96,172	$ (101,948)	$ (5,775)
Common stock discount amortization											0	0	85	0	85
Warrants underlying common stock issuance											$ 0	$ 0	(85)	0	(85)
Released restricted stock units (in shares)											0	1,773
Released restricted stock units											$ 0	$ 0	0	0	0
Stock compensation expense											0	0	21	0	21
Net loss											$ 0	$ 0	0	(5,300)	(5,300)
Conversion of subordinated convertible notes into shares of common stock (in shares)						0	329,086
Conversion of subordinated convertible notes into shares of common stock						$ 0	$ 0	$ 2,914	$ 0	$ 2,914
Balance (in shares) at Mar. 31, 2023											0	979,243
Balance at Mar. 31, 2023											$ 0	$ 1	99,107	(107,248)	(8,140)
Balance (in shares) at Dec. 31, 2022											0	648,384
Balance at Dec. 31, 2022											$ 0	$ 1	96,172	(101,948)	(5,775)
Net loss															(16,258)
Balance (in shares) at Sep. 30, 2023											14,000	1,176,260
Balance at Sep. 30, 2023											$ 0	$ 1	113,716	(118,206)	(4,488)
Balance (in shares) at Mar. 31, 2023											0	979,243
Balance at Mar. 31, 2023											$ 0	$ 1	99,107	(107,248)	(8,140)
Common stock discount amortization											0	0	86	0	86
Warrants underlying common stock issuance											0	0	(86)	0	(86)
Released restricted stock units											$ 0	$ 0	8,000	0	8,000
Issuance of shares (in shares)											0	197,017
Stock compensation expense											$ 0	$ 0	35	0	35
Net loss											0	0	0	(6,764)	(6,764)
Issuance of shares												0	659	0	659
Stock issuance costs											$ 0	$ 0	(85)	0	(85)
Balance (in shares) at Jun. 30, 2023											8,000	1,176,260
Balance at Jun. 30, 2023											$ 0	$ 1	107,716	(114,012)	(6,295)
Common stock discount amortization											0	0	87	0	87
Warrants underlying common stock issuance											0	0	(87)	0	(87)
Released restricted stock units											0	0	0	0	0
Issuance of shares (in shares)	6,000	0
Issuance of convertible preferred stock	$ 0	$ 0	$ 6,000	$ 0	$ 6,000
Stock compensation expense											0	0	26	0	26
Net loss											0	0	0	(4,194)	(4,194)
Stock issuance costs											$ 0	$ 0	(26)	0	(26)
Balance (in shares) at Sep. 30, 2023											14,000	1,176,260
Balance at Sep. 30, 2023											$ 0	$ 1	113,716	(118,206)	(4,488)
Balance (in shares) at Dec. 31, 2023											14,000	1,258,460
Balance at Dec. 31, 2023											$ 0	$ 1	113,775	(122,897)	(9,121)
Common stock discount amortization											0	0	86	0	86
Warrants underlying common stock issuance											$ 0	$ 0	(86)	0	(86)
Released restricted stock units (in shares)											0	29,775
Released restricted stock units											$ 0	$ 0	0	0	0
Issuance of shares (in shares)	8,000	0
Issuance of convertible preferred stock	$ 0	$ 0	8,000	0	8,000
Stock compensation expense											0	0	57	0	57
Net loss											$ 0	$ 0	0	(6,147)	(6,147)
Balance (in shares) at Mar. 31, 2024											22,000	1,288,235
Balance at Mar. 31, 2024											$ 0	$ 1	121,832	(129,044)	(7,211)
Balance (in shares) at Dec. 31, 2023											14,000	1,258,460
Balance at Dec. 31, 2023											$ 0	$ 1	113,775	(122,897)	(9,121)
Net loss															(20,407)
Balance (in shares) at Sep. 30, 2024											33,835	1,545,920
Balance at Sep. 30, 2024											$ 0	$ 1	134,015	(143,304)	(9,288)
Balance (in shares) at Mar. 31, 2024											22,000	1,288,235
Balance at Mar. 31, 2024											$ 0	$ 1	121,832	(129,044)	(7,211)
Common stock discount amortization											0	0	86	0	86
Warrants underlying common stock issuance											$ 0	$ 0	(86)	0	(86)
Released restricted stock units (in shares)											0	254,185
Released restricted stock units											$ 0	$ 0	0	0	0
Issuance of shares (in shares)	8,838	0
Issuance of convertible preferred stock	$ 0	$ 0	8,838	0	8,838
Stock compensation expense											0	0	29	0	29
Net loss											$ 0	$ 0	0	(6,825)	(6,825)
Balance (in shares) at Jun. 30, 2024											30,838	1,542,420
Balance at Jun. 30, 2024											$ 0	$ 1	130,699	(135,869)	(5,169)
Common stock discount amortization											0	0	70	0	70
Warrants underlying common stock issuance											$ 0	$ 0	(70)	0	(70)
Released restricted stock units (in shares)											0	3,500
Released restricted stock units											$ 0	$ 0	0	0	0
Issuance of shares (in shares)	2,997	0
Issuance of convertible preferred stock	$ 0	$ 0	$ 2,997	$ 0	$ 2,997
Stock compensation expense											0	0	319	0	319
Net loss											$ 0	$ 0	0	(7,435)	(7,435)
Balance (in shares) at Sep. 30, 2024											33,835	1,545,920
Balance at Sep. 30, 2024											$ 0	$ 1	$ 134,015	$ (143,304)	$ (9,288)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (20,407,000)	$ (16,258,000)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation	1,666,000	1,666,000
Operating lease non-cash expense	469,000	425,000
Stock compensation expense	405,000	83,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(20,000)	(512,000)
Accounts payable	(443,000)	(2,884,000)
Interest payable	2,996,000	1,181,000
Accrued litigation liability	0	1,088,000
Accrued expenses and other current liabilities	(7,000)	(168,000)
Operating lease liability	(469,000)	(437,000)
Net cash used for operating activities	(15,810,000)	(15,816,000)
Cash flows from investing activities:
Purchases of property and equipment	(338,000)	(98,000)
Net cash used for investing activities	(338,000)	(98,000)
Cash flows from financing activities:
Proceeds from senior secured convertible note payable	16,000,000	19,600,000
Proceeds from issuance of common stock	0	659,000
Stock issuance costs	0	(110,000)
Borrowings from note payable	400,000	0
Repayments of note payable	(400,000)	(500,000)
Net cash provided by financing activities	16,000,000	19,649,000
Net change in cash and cash equivalents and restricted cash	(148,000)	3,735,000
Cash and cash equivalents and restricted cash:
Beginning of period	3,204,000	645,000
End of period	3,056,000	4,380,000
Supplemental disclosures of cash flow information:
Cash paid for interest on note payable	13,000	39,000
Non-cash investing and financing activities:
Conversion of accrued interest into subordinated convertible promissory note	1,240,000	0
Stock issuance costs in accounts payable	0	1,000
Property and equipment in accounts payable	0	13,000
Deferred financing costs forgiven	0	365,000
Exchange Agreement, Senior Secured Convertible Promissory Note for Preferred Shares [Member]
Non-cash investing and financing activities:
Exchange of 25% senior convertible promissory notes and accrued interest into convertible preferred stock	17,600,000	14,000,000
Conversion of Accrued Interest Into Preferred Stock [Member]
Non-cash investing and financing activities:
Exchange of 25% senior convertible promissory notes and accrued interest into convertible preferred stock	2,235,000	0
Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member]
Non-cash investing and financing activities:
Conversion of subordinated convertible promissory notes into common stock	$ 0	$ 2,914,000

Statement of Cash Flows

Statement of Cash Flows - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023
Cash and cash equivalents	$ 2,924	$ 4,380
Restricted cash	132	0
Total cash and cash equivalents and restricted cash	$ 3,056	$ 4,380

Note 1 - Organization

Note 1 - Organization	9 Months Ended
Note 1 - Organization	Sep. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. ORGANIZATION Nature of Business Kiromic BioPharma, Inc. and subsidiaries (the "Company" or “We”) are a clinical stage, fully integrated biotherapeutics company formed under the Texas Business Organizations Code in December 2012. not We are an allogeneic Gamma Delta T-cell therapy company featuring unique, proprietary end-to-end bioinformatic, AI targeting and manufacturing technologies to address solid tumors. Our end-to-end approach consists of target discovery and validation, product development, and on-site current Good Manufacturing Practices (“cGMP”) which we believe will allow us to leverage a new framework for the next generation of cell therapies. From a development standpoint, we utilize innovative non-engineered and engineered allogeneic Gamma Delta T (GDT) cell technologies and are developing proprietary, virus-free cell engineering methods to develop novel therapies for solid tumors that we believe will be effective and cost-efficient. Deltacel™ (Deltacel) is our first 1 2 L1. ex-vivo L1 We have a total of five 1 Deltacel- 01: 4 August 2024. second September 2024. 2 Isocel combination: This clinical trial will evaluate Isocel in combination with low-dose radiation for patients with Mesothelin Isoform 2 3 Alexis-ISO- 1: 2 4 Procel combination: This clinical trial will evaluate Procel in combination with low-dose radiation for patients with PD- L1 5 Alexis-PRO- 1: L1 Depending on pre-clinical evidence, we might submit 1 1 two Going Concern The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $15.8 million for the nine September 30, 2024 September 30, 2024 not twelve Given its projected operating requirements and its existing cash and cash equivalents, management’s plans include evaluating different strategies to obtain the required funding for future operations. These plans may not no not may The condensed consolidated financial statements do not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
Note 2 - Summary of Significant Accounting Policies	Sep. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification ("ASC") 270, 10‑Q 10 X. not not may Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10 December 31, 2023 September 30, 2024 not may December 31, 2023 All intercompany balances were eliminated upon consolidation. Use of Estimates third Concentrations of Credit Risk and Other Uncertainties may not not The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third Restricted Cash zero September 30, 2024 December 31, 2023, Property and Equipment Impairment of Long-Lived Assets no Income Taxes may may Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not The Company records uncertain tax positions in accordance with Accounting Standard Codification (“ASC 740” Income Taxes two 1 not 2 not 50 three nine September 30, 2024 2023 Research and Development Expense The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not Nonvested Stock Options, Restricted Stock Units and Awards 2017 “2017 2021 “2021 The vesting conditions for stock options and RSUs include annual and monthly vesting. Annual vesting conditions are for three The vesting conditions for RSAs include cliff vesting conditions. Certain RSUs vest with a range of 6 to 12 months. When RSUs vest, they are released to the grantee within sixty Stock-Based Compensation 2017 “2017 2021 “2021 718, Compensation Stock Compensation The Company estimates the grant date fair value of stock options using the Black‑Scholes model and the assumptions used to value such stock options are determined as follows: Expected Term. not Risk Free Interest Rate. Volatility. no Dividend Yield. not Common Stock Valuations Segment Data Recently Issued Accounting Pronouncements Accounting Standards Not Segments . November 2023, No. 2023 07, 280 2023 07 December 15, 2023, December 15, 2024, one not Income Taxes . December 2023, No. 2023 09, 740 2023 09 December 15, 2024,

Note 3 - Net Loss Per Common St

Note 3 - Net Loss Per Common Stock Share	9 Months Ended
Note 3 - Net Loss Per Common Stock Share	Sep. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	3. NET LOSS PER COMMON STOCK SHARE Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented the common shares underlying the stock options, RSUs and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares is the same. The following table illustrates the computation of basic and diluted loss per share: Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2024 2023 2024 2023 Net loss $ (7,435 ) $ (4,194 ) (20,407 ) (16,258 ) Less: Initial Public Offering Common Stock discount amortization (8 ) (25 ) (58 ) (75 ) Less: Public Offering Common Stock discount amortization (62 ) (62 ) (184 ) (183 ) Less: Undeclared dividends attributable to convertible preferred stock (1,951 ) (808 ) (4,272 ) (1,323 ) Net loss attributable to common shareholders $ (9,457 ) $ (5,089 ) (24,922 ) (17,839 ) Three Months Ended Three Months Ended September 30, 2024 September 30, 2023 (In thousands, except share and per share amounts) Common Stock Preferred Stock Common Stock Preferred Stock Net loss per share, basic and diluted Allocation of undistributed net loss $ (1,008 ) $ (8,449 ) $ (1,811 ) $ (3,278 ) Weighted average shares outstanding, basic and diluted 1,545,920 30,968 1,189,989 12,891 Basic and diluted net loss per share $ (0.65 ) $ (272.82 ) $ (1.52 ) $ (254.26 ) Nine Months Ended Nine Months Ended September 30, 2024 September 30, 2023 Common Stock Preferred Stock Common Stock Preferred Stock Net loss per share, basic and diluted Allocation of undistributed net loss $ (2,957 ) $ (21,965 ) $ (8,765 ) $ (9,074 ) Weighted average shares outstanding, basic and diluted 1,432,787 22,793 1,040,190 7,011 Basic and diluted net loss per share $ (2.06 ) $ (963.64 ) $ (8.43 ) $ (1,294.31 ) For the three September 30, 2024 During the nine September 30, 2024 three first second third 10

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	9 Months Ended
Note 4 - Property and Equipment, Net	Sep. 30, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. PROPERTY AND EQUIPMENT, NET Property and equipment, net consisted of the following: (In thousands) September 30, 2024 December 31, 2023 Equipment $ 3,336 $ 3,126 Leasehold improvements 7,372 7,372 Office furniture, fixtures, and equipment 137 137 Software 589 360 Construction in progress — 101 11,434 11,096 Less: Accumulated depreciation (6,587 ) (4,921 ) Total $ 4,847 $ 6,175 Depreciation expense was $552 thousand and $560 thousand for the three September 30, 2024 2023 nine September 30, 2024 2023

Note 5 - Accrued Expenses and O

Note 5 - Accrued Expenses and Other Current Liabilities	9 Months Ended
Note 5 - Accrued Expenses and Other Current Liabilities	Sep. 30, 2024
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following as of: (In thousands) September 30, 2024 December 31, 2023 Accrued litigation and settlements $ 130 $ 448 Accrued compensation 1,116 865 Accrued consulting and outside services 420 360 Total $ 1,666 $ 1,673

Note 6 - Note Payable

Note 6 - Note Payable	9 Months Ended
Note 6 - Note Payable	Sep. 30, 2024
Notes to Financial Statements
Schedule of Short-Term Debt [Table Text Block]	6. NOTE PAYABLE In January 2024, eleven September 30, 2024 December 31, 2023,

Note 7 - Senior Secured Convert

Note 7 - Senior Secured Convertible Promissory Note	9 Months Ended
Note 7 - Senior Secured Convertible Promissory Note	Sep. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	7. SENIOR SECURED CONVERTIBLE PROMISSORY NOTE The Company began issuing senior secured convertible promissory notes (each a “CPN” and together the “Notes”) during 2022. Through September 30, 2024 twenty-two nine September 30, 2024 25% one The stated interest rates for these notes increase to 27% per annum or the highest rate then allowed under applicable law (whichever is lower) upon the occurrence of an event of default, including the failure by the Company to make payment of principal or interest due under the related note on the respective maturity date, and any commencement by the Company of a case under any applicable bankruptcy or insolvency law. In April 2023, July 2023, March 2024, June 2024 September 2024, 10— Senior secured convertible promissory notes consisted of the following: (In thousands) Issue Date Maturity Date September 30, 2024 December 31, 2023 06/26/2023 06/26/2024 $ — $ 2,400 07/25/2023 07/25/2024 — 2,400 08/25/2023 08/25/2024 — 2,400 09/27/2023 09/27/2024 — 2,400 11/02/2023 11/02/2024 2,400 2,400 12/12/2023 12/12/2024 — 2,000 04/02/2024 04/02/2025 2,000 — 05/02/2024 05/02/2025 2,000 — 06/03/2024 06/03/2025 2,000 — 06/21/2024 06/21/2025 1,240 — 07/03/2024 07/03/2025 2,000 — 08/01/2024 08/01/2025 2,000 — Total senior secured convertible promissory notes $ 13,640 $ 14,000

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
Note 8 - Commitments and Contingencies	Sep. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. COMMITMENTS AND CONTINGENCIES License Agreements The Company has entered into a number of licensing arrangements for various intellectual property and licensed patent rights for technologies being developed for commercial sale. As part of these arrangements, the Company is subject to contingent milestone payments in accordance with agreed-upon development objectives, as well as future royalty payments on product sales of the underlying assets. As of September 30, 2024 December 31, 2023 not Legal Proceedings Jason Terrel Claim On March 22, 2021, No. 2021 0248 2014 January 2017 On January 31, 2024, 2021, third not March 11, 2024, January 31, 2024, May 9, 2024; June 25, 2024. October 30, 2024, Karp and Podmore Class Actions On August 5, 2022, July 2, 2021, 11, 12, 15 1933 July 2, 2021 10 1934 10b 5 June 25, 2021 August 13, 2021. October 3, 2022, The Karp Class Action and the Podmore Class Action were consolidated and are collectively referred to as the “Class Action”. Please refer to the Settlement of the Class Action described more fully below. Settlement in Principle of the Class Action On August 7, 2023, September 29, 2023, September 30, 2024 December 31, 2023 The Company regularly assesses all contingencies and believes, based on information presently known, the Company is not

Note 9 - Leases

Note 9 - Leases	9 Months Ended
Note 9 - Leases	Sep. 30, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. LEASES The Company leases real estate for office and warehouse space under non-cancelable operating leases, with a total rentable space of 149,000 square feet. The Company intends to use the full lease term under the existing lease agreement which is currently set to expire on April 30, 2026. September 30, 2024 not There are no variable payments associated with the lease agreements, as the rent payments are predetermined on a fixed schedule. The following table indicates the balance sheet line items that include the right-of-use assets and lease liabilities for our operating lease: (In thousands) September 30, 2024 December 31, 2023 Operating lease Operating lease Right-of-Use Asset Operating lease, net $ 1,074 $ 1,543 Total right-of use asset, net $ 1,074 $ 1,543 Lease Liabilities Operating lease - short term $ (670 ) $ (631 ) Operating lease - long term (404 ) (912 ) Total lease liabilities $ (1,074 ) $ (1,543 ) For the three nine September 30, 2024 2023 Three Months Ended Nine Months Ended (In thousands) September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Operating lease cost allocated to research and development expense $ 113 $ 109 $ 338 $ 288 Operating lease cost allocated to general and administrative expense 66 70 199 249 Total lease expense $ 179 $ 179 $ 537 $ 537 Weighted-average remaining lease term 1.59 2.59 1.59 2.59 Weighted-average discount rate 7.12 % 7.12 % 7.12 % 7.12 % As of September 30, 2024 Maturity of Lease Liabilities (In thousands) Operating lease 2024 (remaining) $ 179 2025 725 2026 242 Total lease payments 1,146 Less: imputed interest (72 ) Present value of lease payments $ 1,074

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	9 Months Ended
Note 10 - Stockholders' Equity	Sep. 30, 2024
Notes to Financial Statements
Equity [Text Block]	10. STOCKHOLDERS EQUITY Common Stock one Preferred Stock September 30, 2024 December 31, 2023 1 none September 30, 2024 December 31, 2023 April 2, 2023, July 18, 2023, March 28, 2024, June 21, 2024, September 27, 2024, five As discussed in Note 3, two 2024, three 5 fifth one one Cumulative Rights of Series C, D and E Stock Shareholders Dividends Earned for the period Ended September 30, 2024 Liquidation Preference (In thousands) Three Months Ended Nine Months Ended September 30, 2024 December 31, 2023 Series C $ 882 $ 2,627 $ 18,833 $ 16,205 Series D 1,061 1,637 18,474 - Series E 8 8 3,005 - Total $ 1,951 $ 4,272 $ 40,312 $ 16,205 Participating Rights of Series C, D and E Stock Shareholders Warrants five may October 14, 2025, July 1, 2026. September 30, 2024 December 31, 2023 Standby Equity Purchase Agreement Financing On October 13, 2022, October 13, 2022, first 24 On May 24, 2023, On June 2, 2023,

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	9 Months Ended
Note 11 - Stock-based Compensation	Sep. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	11. STOCK-BASED COMPENSATION 2017 Restricted Stock Units The following table summarizes the activity for all RSUs outstanding under the 2017 September 30, 2024 2023 2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Outstanding RSUs at beginning of period 605 $ 285.36 650 $ 259.50 Granted — — — — Vested (52 ) 259.97 (246 ) 255.85 Cancelled and forfeited (537 ) 254.10 (45 ) 260.10 Nonvested RSUs as of September 30 16 $ 260.08 359 $ 285.36 In addition, the weighted average remaining recognition period for the 2017 September 30, 2024 Total stock compensation expense recognized from stock-based compensation awards classified as restricted stock units were recognized in the condensed consolidated statements of operations for the three nine September 30, 2024 2023 Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2024 2023 2024 2023 Research and development $ — $ 6 $ 9 $ 21 General and administrative — 9 15 23 Total $ — $ 15 $ 24 $ 44 As of September 30, 2024 2017 2017 Stock Options The following table summarizes the activity for all stock options outstanding as of September 30, 2024 2023 2017 2024 2023 Weighted Weighted Average Average Exercise Exercise Shares Price Shares Price Options outstanding at beginning of period 18,093 $ 101.04 32,706 $ 96.24 Granted — — — — Exercised — — — — Cancelled and forfeited — — (14,613 ) 88.17 Balance as of September 30 18,093 $ 101.04 18,093 $ 101.04 Options exercisable as of September 30: 18,093 $ 101.04 18,093 $ 101.04 The options have no intrinsic value as of September 30, 2024 December 31, 2023 There was no stock compensation expense recognized for stock options in the condensed consolidated statements of operations for the three nine September 30, 2024 2023 As of September 30, 2024 2021 Restricted Stock Units The following table summarizes the activity for all RSUs outstanding as of September 30, 2024 2023 2021 2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Outstanding RSUs at beginning of period 89,206 $ 1.56 684 $ 133.20 Granted 92,444 2.57 50,843 0.62 Vested (29,775 ) 4.95 (13,483 ) 0.62 Cancelled and forfeited (95,652 ) 1.89 (621 ) 126.60 Nonvested RSUs as of September 30 56,223 $ 3.74 37,423 $ 20.41 In addition, the weighted average remaining recognition period for the 2021 September 30, 2024 Total stock compensation expense recognized from stock-based compensation awards classified as restricted stock units were recognized in the condensed consolidated statements of operations for the three nine September 30, 2024 2023 Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2024 2023 2024 2023 Research and development $ — $ 10 $ 24 $ 21 General and administrative — 2 38 17 Total $ — $ 12 $ 62 $ 38 As of September 30, 2024 2021 2021 Restricted Stock Awards In May 2024, not September 30, 2024 The following table summarizes the activity for all RSAs outstanding as of September 30, 2024 2023 2021 2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Nonvested RSAs at beginning of period — $ — — $ — Granted 254,185 2.42 — — Vested — — — — Cancelled and forfeited — — — — Nonvested RSAs as of September 30 254,185 $ 2.42 — $ — In addition, the weighted average remaining recognition period for the RSAs is 0.49 years as of September 30, 2024 Total stock compensation expense recognized from stock-based compensation awards classified as restricted stock awards were recognized in the condensed consolidated statements of operations for the three nine September 30, 2024 2023 Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2024 2023 2024 2023 Research and development $ 107 $ — $ 107 $ — General and administrative 212 — 212 — Total $ 319 $ — $ 319 $ — As of September 30, 2024

Note 12 - Income Taxes

Note 12 - Income Taxes	9 Months Ended
Note 12 - Income Taxes	Sep. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. INCOME TAXES The Company’s effective tax rate from continuing operations was 0% for the three nine September 30, 2024 2023 three nine September 30, 2024 The provision for income taxes during the interim reporting periods is calculated by applying an estimate of the annual effective tax rate for the full fiscal year to “ordinary” income or loss for the reporting period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws, business reorganizations and settlements with taxing authorities. The income tax rates vary from the US federal statutory rate of 21% primarily due to the full valuation allowance on the Company’s deferred tax assets. The Company has recorded the full valuation allowance based on an evaluation of both positive and negative evidence, including latest forecasts and cumulative losses in recent years. The Company has concluded that it was more likely than not none

Note 13 - Subsequent Events

Note 13 - Subsequent Events	9 Months Ended
Note 13 - Subsequent Events	Sep. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	13. SUBSEQUENT EVENTS On November 1, 2024, $600 5 fifth On November 3, 2024,

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
Insider Trading Arrangements	Sep. 30, 2024	Sep. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		ITEM 5. None
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification ("ASC") 270, 10‑Q 10 X. not not may Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10 December 31, 2023 September 30, 2024 not may December 31, 2023 All intercompany balances were eliminated upon consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates third
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Other Uncertainties may not not The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash zero September 30, 2024 December 31, 2023,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets no
Income Tax, Policy [Policy Text Block]	Income Taxes may may Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not The Company records uncertain tax positions in accordance with Accounting Standard Codification (“ASC 740” Income Taxes two 1 not 2 not 50 three nine September 30, 2024 2023
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not
Share-Based Payment Arrangement [Policy Text Block]	Nonvested Stock Options, Restricted Stock Units and Awards 2017 “2017 2021 “2021 The vesting conditions for stock options and RSUs include annual and monthly vesting. Annual vesting conditions are for three The vesting conditions for RSAs include cliff vesting conditions. Certain RSUs vest with a range of 6 to 12 months. When RSUs vest, they are released to the grantee within sixty Stock-Based Compensation 2017 “2017 2021 “2021 718, Compensation Stock Compensation The Company estimates the grant date fair value of stock options using the Black‑Scholes model and the assumptions used to value such stock options are determined as follows: Expected Term. not Risk Free Interest Rate. Volatility. no Dividend Yield. not Common Stock Valuations
Segment Reporting, Policy [Policy Text Block]	Segment Data
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements Accounting Standards Not Segments . November 2023, No. 2023 07, 280 2023 07 December 15, 2023, December 15, 2024, one not Income Taxes . December 2023, No. 2023 09, 740 2023 09 December 15, 2024,

Note 3 - Net Loss Per Common _2

Note 3 - Net Loss Per Common Stock Share (Tables)	9 Months Ended
Note 3 - Net Loss Per Common Stock Share (Tables)	Sep. 30, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2024 2023 2024 2023 Net loss $ (7,435 ) $ (4,194 ) (20,407 ) (16,258 ) Less: Initial Public Offering Common Stock discount amortization (8 ) (25 ) (58 ) (75 ) Less: Public Offering Common Stock discount amortization (62 ) (62 ) (184 ) (183 ) Less: Undeclared dividends attributable to convertible preferred stock (1,951 ) (808 ) (4,272 ) (1,323 ) Net loss attributable to common shareholders $ (9,457 ) $ (5,089 ) (24,922 ) (17,839 ) Three Months Ended Three Months Ended September 30, 2024 September 30, 2023 (In thousands, except share and per share amounts) Common Stock Preferred Stock Common Stock Preferred Stock Net loss per share, basic and diluted Allocation of undistributed net loss $ (1,008 ) $ (8,449 ) $ (1,811 ) $ (3,278 ) Weighted average shares outstanding, basic and diluted 1,545,920 30,968 1,189,989 12,891 Basic and diluted net loss per share $ (0.65 ) $ (272.82 ) $ (1.52 ) $ (254.26 ) Nine Months Ended Nine Months Ended September 30, 2024 September 30, 2023 Common Stock Preferred Stock Common Stock Preferred Stock Net loss per share, basic and diluted Allocation of undistributed net loss $ (2,957 ) $ (21,965 ) $ (8,765 ) $ (9,074 ) Weighted average shares outstanding, basic and diluted 1,432,787 22,793 1,040,190 7,011 Basic and diluted net loss per share $ (2.06 ) $ (963.64 ) $ (8.43 ) $ (1,294.31 )

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment, Net (Tables)	9 Months Ended
Note 4 - Property and Equipment, Net (Tables)	Sep. 30, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	(In thousands) September 30, 2024 December 31, 2023 Equipment $ 3,336 $ 3,126 Leasehold improvements 7,372 7,372 Office furniture, fixtures, and equipment 137 137 Software 589 360 Construction in progress — 101 11,434 11,096 Less: Accumulated depreciation (6,587 ) (4,921 ) Total $ 4,847 $ 6,175

Note 5 - Accrued Expenses and_2

Note 5 - Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	(In thousands) September 30, 2024 December 31, 2023 Accrued litigation and settlements $ 130 $ 448 Accrued compensation 1,116 865 Accrued consulting and outside services 420 360 Total $ 1,666 $ 1,673

Note 7 - Senior Secured Conve_2

Note 7 - Senior Secured Convertible Promissory Note (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Convertible Debt [Table Text Block]	(In thousands) Issue Date Maturity Date September 30, 2024 December 31, 2023 06/26/2023 06/26/2024 $ — $ 2,400 07/25/2023 07/25/2024 — 2,400 08/25/2023 08/25/2024 — 2,400 09/27/2023 09/27/2024 — 2,400 11/02/2023 11/02/2024 2,400 2,400 12/12/2023 12/12/2024 — 2,000 04/02/2024 04/02/2025 2,000 — 05/02/2024 05/02/2025 2,000 — 06/03/2024 06/03/2025 2,000 — 06/21/2024 06/21/2025 1,240 — 07/03/2024 07/03/2025 2,000 — 08/01/2024 08/01/2025 2,000 — Total senior secured convertible promissory notes $ 13,640 $ 14,000

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	9 Months Ended
Note 9 - Leases (Tables)	Sep. 30, 2024
Notes Tables
Lessee, Operating Lease [Table Text Block]	(In thousands) September 30, 2024 December 31, 2023 Operating lease Operating lease Right-of-Use Asset Operating lease, net $ 1,074 $ 1,543 Total right-of use asset, net $ 1,074 $ 1,543 Lease Liabilities Operating lease - short term $ (670 ) $ (631 ) Operating lease - long term (404 ) (912 ) Total lease liabilities $ (1,074 ) $ (1,543 )
Lease, Cost [Table Text Block]	Three Months Ended Nine Months Ended (In thousands) September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Operating lease cost allocated to research and development expense $ 113 $ 109 $ 338 $ 288 Operating lease cost allocated to general and administrative expense 66 70 199 249 Total lease expense $ 179 $ 179 $ 537 $ 537 Weighted-average remaining lease term 1.59 2.59 1.59 2.59 Weighted-average discount rate 7.12 % 7.12 % 7.12 % 7.12 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Maturity of Lease Liabilities (In thousands) Operating lease 2024 (remaining) $ 179 2025 725 2026 242 Total lease payments 1,146 Less: imputed interest (72 ) Present value of lease payments $ 1,074

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	9 Months Ended
Note 10 - Stockholders' Equity (Tables)	Sep. 30, 2024
Notes Tables
Schedule of Stock by Class [Table Text Block]	Dividends Earned for the period Ended September 30, 2024 Liquidation Preference (In thousands) Three Months Ended Nine Months Ended September 30, 2024 December 31, 2023 Series C $ 882 $ 2,627 $ 18,833 $ 16,205 Series D 1,061 1,637 18,474 - Series E 8 8 3,005 - Total $ 1,951 $ 4,272 $ 40,312 $ 16,205

Note 11 - Stock-based Compens_2

Note 11 - Stock-based Compensation (Tables)	9 Months Ended
Note 11 - Stock-based Compensation (Tables)	Sep. 30, 2024
Notes Tables
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Outstanding RSUs at beginning of period 605 $ 285.36 650 $ 259.50 Granted — — — — Vested (52 ) 259.97 (246 ) 255.85 Cancelled and forfeited (537 ) 254.10 (45 ) 260.10 Nonvested RSUs as of September 30 16 $ 260.08 359 $ 285.36 2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Outstanding RSUs at beginning of period 89,206 $ 1.56 684 $ 133.20 Granted 92,444 2.57 50,843 0.62 Vested (29,775 ) 4.95 (13,483 ) 0.62 Cancelled and forfeited (95,652 ) 1.89 (621 ) 126.60 Nonvested RSUs as of September 30 56,223 $ 3.74 37,423 $ 20.41
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2024 2023 2024 2023 Research and development $ — $ 6 $ 9 $ 21 General and administrative — 9 15 23 Total $ — $ 15 $ 24 $ 44 Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2024 2023 2024 2023 Research and development $ — $ 10 $ 24 $ 21 General and administrative — 2 38 17 Total $ — $ 12 $ 62 $ 38 Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2024 2023 2024 2023 Research and development $ 107 $ — $ 107 $ — General and administrative 212 — 212 — Total $ 319 $ — $ 319 $ —
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	2024 2023 Weighted Weighted Average Average Exercise Exercise Shares Price Shares Price Options outstanding at beginning of period 18,093 $ 101.04 32,706 $ 96.24 Granted — — — — Exercised — — — — Cancelled and forfeited — — (14,613 ) 88.17 Balance as of September 30 18,093 $ 101.04 18,093 $ 101.04 Options exercisable as of September 30: 18,093 $ 101.04 18,093 $ 101.04
Nonvested Restricted Stock Shares Activity [Table Text Block]	2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Nonvested RSAs at beginning of period — $ — — $ — Granted 254,185 2.42 — — Vested — — — — Cancelled and forfeited — — — — Nonvested RSAs as of September 30 254,185 $ 2.42 — $ —

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) - USD ($) $ in Thousands	9 Months Ended		142 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer, Excluding Assessed Tax			$ 0
Net Cash Provided by (Used in) Operating Activities	$ (15,810)	$ (15,816)
Retained Earnings (Accumulated Deficit)	$ (143,304)		$ (143,304)	$ (122,897)

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands	3 Months Ended		9 Months Ended		142 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Restricted Cash, Current	$ 132	$ 0	$ 132	$ 0	$ 132	$ 0
Impairment, Long-Lived Asset, Held-for-Use					0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	0	$ 0	0	$ 0
Dividends Payable	$ 0		$ 0		$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0%
Number of Reportable Segments	1
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	1 year		1 year		1 year
Minimum [Member] \| Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	10 months
Minimum [Member] \| Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	6 months
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	8 years		8 years		8 years
Maximum [Member] \| Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	48 months
Maximum [Member] \| Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	12 months

Note 3 - Net Loss Per Common _3

Note 3 - Net Loss Per Common Stock Share (Details Textual) - USD ($)				1 Months Ended			3 Months Ended	9 Months Ended
	Mar. 28, 2024	Jul. 18, 2023	Apr. 02, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Exchange Agreement, Senior Secured Convertible Promissory Note for Preferred Shares [Member]
Debt Conversion, Original Debt, Amount	$ 8	$ 6	$ 8		$ 7,200,000	$ 8	$ 2,400,000	$ 17,600,000	$ 14,000,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)					8,837.58	8,000	2,997
Debt Conversion, Original Accrued Interest, Amount					$ 1,630,000		$ 0.59
Debt Conversion, Original Debt and Accrued Interest, Amount				$ 3	$ 8.8		$ 3
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)							56,239
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)							15,416

Note 3 - Net Loss Per Common _4

Note 3 - Net Loss Per Common Stock Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Net loss	$ (7,435)	$ (6,825)	$ (6,147)	$ (4,194)	$ (6,764)	$ (5,300)	$ (20,407)	$ (16,258)
Less: Undeclared dividends attributable to convertible preferred stock	(1,951)			(808)			(4,272)	(1,323)
Net loss attributable to common shareholders	(9,457)			(5,089)			(24,922)	(17,839)
IPO [Member]
Less: Public Offering Common Stock discount amortization	(8)			(25)			(58)	(75)
Public Offering [Member]
Less: Public Offering Common Stock discount amortization	(62)			(62)			(184)	(183)
Common Stock [Member]
Net loss	0	0	0	0	0	0
Allocation of undistributed net loss	$ (1,008)			$ (1,811)			$ (2,957)	$ (8,765)
Weighted average shares outstanding, basic and diluted (in shares)	1,545,920			1,189,989			1,432,787	1,040,190
Basic and diluted net loss per share (in dollars per share)	$ (0.65)			$ (1.52)			$ (2.06)	$ (8.43)
Preferred Stock [Member]
Net loss	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Allocation of undistributed net loss	$ (8,449)			$ (3,278)			$ (21,965)	$ (9,074)
Weighted average shares outstanding, basic and diluted (in shares)	30,968			12,891			22,793	7,011
Basic and diluted net loss per share (in dollars per share)	$ (272.82)			$ (254.26)			$ (963.64)	$ (1,294.31)

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Depreciation	$ 552	$ 560	$ 1,666	$ 1,666

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Equipment	$ 3,336	$ 3,126
Leasehold improvements	7,372	7,372
Office furniture, fixtures, and equipment	137	137
Software	589	360
Construction in progress	0	101
Property, Plant and Equipment, Gross	11,434	11,096
Less: Accumulated depreciation	(6,587)	(4,921)
Total	$ 4,847	$ 6,175

Note 5 - Accrued Expenses and_3

Note 5 - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accrued litigation and settlements	$ 130	$ 448
Accrued compensation	1,116	865
Accrued consulting and outside services	420	360
Total	$ 1,666	$ 1,673

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual) - Insurance Policy Financing Arrangement [Member] - Notes Payable [Member] $ in Millions	1 Months Ended
	Jan. 31, 2024 USD ($)
Debt Instrument, Face Amount	$ 0.4
Debt Instrument, Interest Rate, Stated Percentage	4.93%
Debt Instrument, Term (Month)	11 months

Note 7 - Senior Secured Conve_3

Note 7 - Senior Secured Convertible Promissory Note (Details Textual)				1 Months Ended			3 Months Ended	4 Months Ended	9 Months Ended
	Mar. 28, 2024 USD ($)	Jul. 18, 2023 USD ($)	Apr. 02, 2023 USD ($)	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Exchange Agreement, Senior Secured Convertible Promissory Note for Preferred Shares [Member]
Debt Conversion, Original Debt, Amount	$ 8	$ 6	$ 8		$ 7,200,000	$ 8	$ 2,400,000		$ 17,600,000	$ 14,000,000
Debt Conversion, Original Debt and Accrued Interest, Amount				$ 3	$ 8.8		$ 3
Senior Secured Convertible Promissory Note [Member]
Debt Instrument, Convertible, Number Issued				22			22	22	22
Debt Instrument, Face Amount				$ 17,200,000			$ 17,200,000	$ 17,200,000	$ 17,200,000
Debt Instrument, Interest Rate, Stated Percentage				25%			25%	25%	25%
Debt Instrument, Term (Month)								1 year
Senior Secured Convertible Promissory Note [Member] \| Maximum [Member]
Debt Instrument, Face Amount				$ 45,200,000			$ 45,200,000	$ 45,200,000	$ 45,200,000
Debt Instrument, Interest Rate, Stated Percentage				27%			27%	27%	27%

Note 7 - Senior Secured Conve_4

Note 7 - Senior Secured Convertible Promissory Note - Schedule of Convertible Notes (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Convertible promissory note	$ 13,640	$ 14,000
Senior Secured Convertible Promissory Notes 1 [Member]
Maturity date	Jun. 26, 2024
Convertible promissory note	$ 0	2,400
Senior Secured Convertible Promissory Notes 2 [Member]
Maturity date	Jul. 25, 2024
Convertible promissory note	$ 0	2,400
Senior Secured Convertible Promissory Notes 3 [Member]
Maturity date	Aug. 25, 2024
Convertible promissory note	$ 0	2,400
Senior Secured Convertible Promissory Notes 4 [Member]
Maturity date	Sep. 27, 2024
Convertible promissory note	$ 0	2,400
Senior Secured Convertible Promissory Notes 5 [Member]
Maturity date	Nov. 02, 2024
Convertible promissory note	$ 2,400	2,400
Senior Secured Convertible Promissory Notes 6 [Member]
Maturity date	Dec. 12, 2024
Convertible promissory note	$ 0	2,000
Senior Secured Convertible Promissory Notes 7 [Member]
Maturity date	Apr. 02, 2025
Convertible promissory note	$ 2,000	0
Senior Secured Convertible Promissory Notes 8 [Member]
Maturity date	May 02, 2025
Convertible promissory note	$ 2,000	0
Senior Secured Convertible Promissory Notes 9 [Member]
Maturity date	Jun. 03, 2025
Convertible promissory note	$ 2,000	0
Senior Secured Convertible Promissory Notes 10 [Member]
Maturity date	Jun. 21, 2025
Convertible promissory note	$ 1,240	0
Senior Secured Convertible Promissory Notes 11 [Member]
Maturity date	Jul. 03, 2025
Convertible promissory note	$ 2,000	0
Senior Secured Convertible Promissory Notes 12 [Member
Maturity date	Aug. 01, 2025
Convertible promissory note	$ 2,000	$ 0

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	Sep. 29, 2023	Jul. 07, 2023	Sep. 30, 2024	Dec. 31, 2023	Mar. 22, 2021
Estimated Litigation Liability, Current			$ 130,000	$ 448,000
Karp and Podmore Class Actions [Member]
Litigation Settlement, Amount Awarded to Other Party	$ 1,730,000	$ 2,300,000
Insurance Settlements Receivable	$ 570,000
Estimated Litigation Liability, Current				448,000
Licensing Agreements [Member] \| Other Commitments, Contingent Milestone Payments [Member]
Other Commitment			$ 0	$ 0
The 2014 Consulting Agreement [Member] \| Jason Terrel Claim [Member]
Loss Contingency, Damages Sought, Shares (in shares)					16,667
Share Price (in dollars per share)					$ 15
The January 2017 Options Agreement [Member] \| Jason Terrel Claim [Member]
Loss Contingency, Damages Sought, Shares (in shares)					16,667
Share Price (in dollars per share)					$ 5.1

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual) $ in Thousands	3 Months Ended
Note 9 - Leases (Details Textual) $ in Thousands	Sep. 30, 2024 USD ($) ft²
Net Rentable Area (Square Foot) \| ft²	149,000
Variable Lease, Payment \| $	$ 0

Note 9 - Leases - Schedule of O

Note 9 - Leases - Schedule of Operating Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Operating lease right-of-use asset, net	$ 1,074	$ 1,543
Operating lease - short term	(670)	(631)
Operating lease - long term	(404)	(912)
Total lease liabilities	$ (1,074)	$ (1,543)

Note 9 - Leases - Schedule of C

Note 9 - Leases - Schedule of Components of Operating Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating lease expense	$ 179	$ 179	$ 537	$ 537
Weighted-average remaining lease term (Year)	1 year 7 months 2 days	2 years 7 months 2 days	1 year 7 months 2 days	2 years 7 months 2 days
Weighted-average discount rate	7.12%	7.12%	7.12%	7.12%
Research and Development Expense [Member]
Operating lease expense	$ 113	$ 109	$ 338	$ 288
General and Administrative Expense [Member]
Operating lease expense	$ 66	$ 70	$ 199	$ 249

Note 9 - Leases - Schedule of M

Note 9 - Leases - Schedule of Maturity (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
2024 (remaining)	$ 179
2025	725
2026	242
Total lease payments	1,146
Less: imputed interest	(72)
Present value of lease payments	$ 1,074	$ 1,543

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual) - USD ($)			9 Months Ended
Note 10 - Stockholders' Equity (Details Textual) - USD ($)	Jun. 02, 2023	May 24, 2023	Sep. 30, 2024	Sep. 27, 2024	Jun. 21, 2024	Mar. 28, 2024	Dec. 31, 2023	Jul. 18, 2023	Apr. 02, 2023	Oct. 13, 2022
Preferred Stock, Shares Authorized (in shares)			60,000,000				60,000,000
Preferred Stock, Shares Issued (in shares)			33,835				14,000
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.001				$ 0.001
Preferred Stock, Dividend Rate, Percentage			25%
Standby Equity Purchase Agreement [Member]
Stock Purchase Agreement, Value of Shares Authorized for Issuance										$ 8
Stock Issued During Period, Shares, New Issues (in shares)	100,000	97,000
Shares Issued, Price Per Share (in dollars per share)	$ 2.82	$ 3.89
Stock Issued During Period, Value, Issued for Services	$ 282,100	$ 377,000
Warrant [Member]
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, October 14, 2025 Expiration [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			2,083
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 450
Class of Warrant or Right, July 1, 2026 Expiration [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			13,333
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 187.5
Series A-1 Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)			24,000,000				24,000,000
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)			16,500,000				16,500,000
Series C Convertible Voting Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)			14,000				14,000
Preferred Stock, Shares Issued (in shares)								6,000	8,000
Series D Convertible Voting Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)			20,000				0
Preferred Stock, Shares Issued (in shares)					8,837.58	8,000
Series E Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)			6,000				0
Price of Convertible Preferred Stock to Common Stock, Percentage			80%
Series E Convertible Voting Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)				2,997
Series C Preferred Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)			$ 6.5
Series D Preferred Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)			$ 2.5
Series C & D Preferred Stock [Member] \| Kiromic BioPharma Inc [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner			19.99%

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Preferred Shares (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Dividends	$ 1,951	$ 4,272
Liquidation preference	40,312	40,312	$ 16,205
Series C Convertible Voting Preferred Stock [Member]
Dividends	882	2,627
Liquidation preference	18,833	18,833	16,205
Series D Convertible Voting Preferred Stock [Member]
Dividends	1,061	1,637
Liquidation preference	18,474	18,474	0
Series E Convertible Voting Preferred Stock [Member]
Dividends	8	8
Liquidation preference	$ 3,005	$ 3,005	$ 0

Note 11 - Stock-based Compens_3

Note 11 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
The 2017 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)				3 months 18 days
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 3,200			$ 3,200
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	0			0		$ 0
The 2017 Stock Incentive Plan [Member] \| Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	0			0
Share-Based Payment Arrangement, Expense		$ 0	$ 0	0	$ 0
The 2021 Stock Incentive Plan [Member]
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	197,800			$ 197,800
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms (Year)				2 years 10 months 17 days
The 2021 Stock Incentive Plan [Member] \| Restricted Stock [Member]
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	297,000			$ 297,000
Share-Based Payment Arrangement, Expense	$ 319,000		$ 0	$ 319,000	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms (Year)				5 months 26 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				254,185	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)				0

Note 11 - Stock-based Compens_4

Note 11 - Stock-based Compensation - Schedule of Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
The 2017 Stock Incentive Plan [Member]
Nonvested, shares (in shares)	605	650
Nonvested, weighted average grant date fair value (in dollars per share)	$ 285.36	$ 259.5
Granted, shares (in shares)	0	0
Granted, weighted average grant date fair value (in dollars per share)	$ 0	$ 0
Vested, shares (in shares)	(52)	(246)
Vested, weighted average grant date fair value (in dollars per share)	$ 259.97	$ 255.85
Cancelled and forfeited, shares (in shares)	(537)	(45)
Cancelled and forfeited, weighted average grant date fair value (in dollars per share)	$ 254.1	$ 260.1
Nonvested, shares (in shares)	16	359
Nonvested, weighted average grant date fair value (in dollars per share)	$ 260.08	$ 285.36
The 2021 Stock Incentive Plan [Member]
Nonvested, shares (in shares)	89,206	684
Nonvested, weighted average grant date fair value (in dollars per share)	$ 1.56	$ 133.2
Granted, shares (in shares)	92,444	50,843
Granted, weighted average grant date fair value (in dollars per share)	$ 2.57	$ 0.62
Vested, shares (in shares)	(29,775)	(13,483)
Vested, weighted average grant date fair value (in dollars per share)	$ 4.95	$ 0.62
Cancelled and forfeited, shares (in shares)	(95,652)	(621)
Cancelled and forfeited, weighted average grant date fair value (in dollars per share)	$ 1.89	$ 126.6
Nonvested, shares (in shares)	56,223	37,423
Nonvested, weighted average grant date fair value (in dollars per share)	$ 3.74	$ 20.41

Note 11 - Stock-based Compens_5

Note 11 - Stock-based Compensation - Schedule of Stock Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restricted Stock Units (RSUs) [Member] \| The 2017 Stock Incentive Plan [Member]
Stock compensation expense	$ 0	$ 15	$ 24	$ 44
Restricted Stock Units (RSUs) [Member] \| The 2021 Stock Incentive Plan [Member]
Stock compensation expense	0	12	62	38
Restricted Stock [Member] \| The 2021 Stock Incentive Plan [Member]
Stock compensation expense	319	0	319	0
Research and Development Expense [Member] \| Restricted Stock Units (RSUs) [Member] \| The 2017 Stock Incentive Plan [Member]
Stock compensation expense	0	6	9	21
Research and Development Expense [Member] \| Restricted Stock Units (RSUs) [Member] \| The 2021 Stock Incentive Plan [Member]
Stock compensation expense	0	10	24	21
Research and Development Expense [Member] \| Restricted Stock [Member] \| The 2021 Stock Incentive Plan [Member]
Stock compensation expense	107	0	107	0
General and Administrative Expense [Member] \| Restricted Stock Units (RSUs) [Member] \| The 2017 Stock Incentive Plan [Member]
Stock compensation expense	0	9	15	23
General and Administrative Expense [Member] \| Restricted Stock Units (RSUs) [Member] \| The 2021 Stock Incentive Plan [Member]
Stock compensation expense	0	2	38	17
General and Administrative Expense [Member] \| Restricted Stock [Member] \| The 2021 Stock Incentive Plan [Member]
Stock compensation expense	$ 212	$ 0	$ 212	$ 0

Note 11 - Stock-based Compens_6

Note 11 - Stock-based Compensation - Schedule of Stock Options (Details) - The 2017 Stock Incentive Plan [Member] - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Options outstanding, balance (in shares)	18,093	32,706
Options outstanding, balance, weighted average exercise price (in dollars per share)	$ 101.04	$ 96.24
Granted (in shares)	0	0
Granted, weighted average exercise price (in dollars per share)	$ 0	$ 0
Exercised (in shares)	0	0
Exercised, weighted average exercise price (in dollars per share)	$ 0	$ 0
Cancelled and forfeited (in shares)	0	(14,613)
Cancelled and forfeited, weighted average exercise price (in dollars per share)	$ 0	$ 88.17
Options outstanding, balance (in shares)	18,093	18,093
Options outstanding, balance, weighted average exercise price (in dollars per share)	$ 101.04	$ 101.04
Options exercisable as of September 30: (in shares)	18,093	18,093
Options exercisable, weighted average exercise price (in dollars per share)	$ 101.04	$ 101.04

Note 11 - Stock-based Compens_7

Note 11 - Stock-based Compensation - Schedule of Restricted Stock (Details) - The 2021 Stock Incentive Plan [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares	Sep. 30, 2023 $ / shares shares
Options outstanding, balance (in shares)	0	0
Options outstanding, balance, weighted average exercise price (in dollars per share) \| $ / shares	$ 0	$ 0
Vested (in shares)	0	0
Vested, weighted average exercise price	0	0
Options outstanding, balance (in shares)	254,185	0
Options outstanding, balance, weighted average exercise price (in dollars per share) \| $ / shares	$ 2.42	$ 0
Restricted Stock [Member]
Granted, shares (in shares)	254,185	0
Granted, weighted average grant date fair value (in dollars per share) \| $ / shares	$ 2.42	$ 0
Cancelled and forfeited, shares (in shares)	0	0
Cancelled and forfeited, weighted average grant date fair value (in dollars per share) \| $ / shares	$ 0	$ 0

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Effective Income Tax Rate Reconciliation, Percent	0%	0%		0%	0%
Income Tax Expense (Benefit)	$ 0	$ 0		$ 0	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21%		21%

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)					1 Months Ended			3 Months Ended	9 Months Ended
Note 13 - Subsequent Events (Details Textual) - USD ($)	Nov. 02, 2024	Mar. 28, 2024	Jul. 18, 2023	Apr. 02, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Series E Convertible Preferred Stock [Member]
Price of Convertible Preferred Stock to Common Stock, Percentage					80%			80%	80%
Senior Secured Convertible Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage					25%			25%	25%
Subsequent Event [Member] \| Series E Convertible Preferred Stock [Member]
Price of Convertible Preferred Stock to Common Stock, Percentage	80%
Subsequent Event [Member] \| Series E Convertible Preferred Stock [Member] \| Kiromic BioPharma Inc [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner	19.99%
Subsequent Event [Member] \| Senior Secured Convertible Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage	25%
Exchange Agreement, Senior Secured Convertible Promissory Note for Preferred Shares [Member]
Debt Conversion, Original Debt, Amount		$ 8	$ 6	$ 8		$ 7,200,000	$ 8	$ 2,400,000	$ 17,600,000	$ 14,000,000
Debt Conversion, Original Debt and Accrued Interest, Amount					$ 3	$ 8.8		$ 3
Exchange Agreement, Senior Secured Convertible Promissory Note for Preferred Shares [Member] \| Subsequent Event [Member]
Debt Conversion, Original Debt, Amount	$ 2,400,000
Debt Conversion, Original Debt and Accrued Interest, Amount	$ 600